CoChat
Sign Up
Cited by 178

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Rivoltini, Licia, Chiodoni, Claudia, Squarcina, Paola, Tortoreto, Monica, Villa, Antonello, Vergani, Barbara, Bürdek, Maja, Botti, Laura, Arioli, Ivano, Cova, Agata, Mauri, Giorgio, Vergani, Elisabetta, Bianchi, Beatrice, Della Mina, Pamela, Cantone, Laura, Bollati, Valentina, Zaffaroni, Nadia, Gianni, Alessandro Massimo, Colombo, Mario Paolo, Huber, Veronica·2016·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-15-2170

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Exosomes deliver signals to target cells and could thus be exploited as an innovative therapeutic tool. We investigated the ability of membrane TRAIL-armed exosomes to deliver proapoptotic signals to cancer cells and mediate growth inhibition in different tumor models. Experimental Methods and Results: K562 cells, transduced with lentiviral human membrane TRAIL, were used for the production of TRAIL+ exosomes, which were studied by nanoparticle tracking analysis, cytofluorimetry, immunoelectronmicroscopy, Western blot, and ELISA. In vitro, TRAIL+ exosomes induced more pronounced apoptosis (detected by Annexin V/propidium iodide and activated caspase-3) in TRAIL-death receptor (DR)5+ cells (SUDHL4 lymphoma and INT12 melanoma), with respect to the DR5−DR4+KMS11 multiple myeloma. Intratumor injection of TRAIL+ exosomes, but not mock exosomes, induced growth inhibition of SUDHL4 (68%) and INT12 (51%), and necrosis in KMS11 tumors. After rapid blood clearance, systemically administered TRAIL+ exosomes accumulated in the liver, lungs, and spleen and homed to the tumor site, leading to a significant reduction of tumor growth (58%) in SUDHL4-bearing mice. The treatment of INT12-bearing animals promoted tumor necrosis and a not statistically significant tumor volume reduction. In KMS11-bearing mice, despite massive perivascular necrosis, no significant tumor growth inhibition was detected. Conclusions: TRAIL-armed exosomes can induce apoptosis in cancer cells and control tumor progression in vivo. Therapeutic efficacy was particularly evident in intratumor setting, while depended on tumor model upon systemic administration. Thanks to their ability to deliver multiple signals, exosomes thus represent a promising therapeutic tool in cancer. Clin Cancer Res; 22(14); 3499–512. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-2170

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 47

  1. Lemke, 2014, Getting TRAIL back on track for cancer therapy, Cell Death Differ, 21, 1350, 10.1038/cdd.2014.81 · DOI
  2. Fuchs, 2013, TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial, Cancer, 119, 4290, 10.1002/cncr.28353 · DOI
  3. von Pawel, 2014, Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non–small cell lung cancer, Clin Lung Cancer, 15, 188, 10.1016/j.cllc.2013.12.005 · DOI
  4. Graves, 2014, Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity, Cancer Cell, 26, 177, 10.1016/j.ccr.2014.04.028 · DOI
  5. Holland, 2014, Death receptor agonist therapies for cancer, which is the right TRAIL?, Cytokine Growth Factor Rev, 25, 185, 10.1016/j.cytogfr.2013.12.009 · DOI
  6. Jiang, 2014, GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial, Eur J Pharmacol, 740, 722, 10.1016/j.ejphar.2014.06.002 · DOI
  7. Tuthill, 2015, TRAIL-R2–specific antibodies and recombinant TRAIL can synergise to kill cancer cells, Oncogene, 34, 2138, 10.1038/onc.2014.156 · DOI
  8. Trivedi, 2015, Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells, Front Oncol, 5, 69, 10.3389/fonc.2015.00069 · DOI
  9. Abdulghani, 2013, Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis, PLoS ONE, 8, e75414, 10.1371/journal.pone.0075414 · DOI
  10. Reagan, 2012, Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ, J Breast Cancer, 15, 273, 10.4048/jbc.2012.15.3.273 · DOI
  11. Carlo-Stella, 2006, Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand, Hum Gene Ther, 17, 1225, 10.1089/hum.2006.17.1225 · DOI
  12. Loi, 2014, sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with bortezomib, J Control Release, 192, 157, 10.1016/j.jconrel.2014.07.009 · DOI
  13. Seifert, 2014, Immuno-LipoTRAIL: targeted delivery of TRAIL-functionalized liposomal nanoparticles, Bioconjug Chem, 25, 879, 10.1021/bc400517j · DOI
  14. De Miguel, 2013, Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells, Mol Pharm, 10, 893, 10.1021/mp300258c · DOI
  15. Mitchell, 2014, TRAIL-coated leukocytes that kill cancer cells in the circulation, Proc Natl Acad Sci U S A, 111, 930, 10.1073/pnas.1316312111 · DOI
  16. EL Andaloussi, 2013, Extracellular vesicles: biology and emerging therapeutic opportunities, Nat Rev Drug Discov, 12, 347, 10.1038/nrd3978 · DOI · Paper page
  17. Lötvall, 2014, Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles, J Extracell Vesicles, 3, 26913, 10.3402/jev.v3.26913 · DOI · Paper page
  18. Colombo, 2014, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu Rev Cell Dev Biol, 30, 255, 10.1146/annurev-cellbio-101512-122326 · DOI · Paper page
  19. Villarroya-Beltri, 2014, Sorting it out: regulation of exosome loading, Semin Cancer Biol, 28, 3, 10.1016/j.semcancer.2014.04.009 · DOI
  20. Webber, 2015, Extracellular vesicles as modulators of the cancer microenvironment, Semin Cell Dev Biol, 40, 27, 10.1016/j.semcdb.2015.01.013 · DOI
  21. Whiteside, 2013, Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes), Biochem Soc Trans, 41, 245, 10.1042/BST20120265 · DOI
  22. Zocco, 2014, Extracellular vesicles as shuttles of tumor biomarkers and antitumor drugs, Front Oncol, 4, 267, 10.3389/fonc.2014.00267 · DOI
  23. Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J Control Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  24. Emanueli, 2015, Exosomes and exosomal miRNAs in cardiovascular protection and repair, Vascul Pharmacol, 71, 24, 10.1016/j.vph.2015.02.008 · DOI
  25. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non–small cell lung cancer, J Transl Med, 3, 9, 10.1186/1479-5876-3-9 · DOI
  26. Escudier, 2005, Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial, J Transl Med, 3, 10, 10.1186/1479-5876-3-10 · DOI
  27. Pitt, 2014, Dendritic cell–derived exosomes as immunotherapies in the fight against cancer, J Immunol, 193, 1006, 10.4049/jimmunol.1400703 · DOI
  28. Guenechea, 2000, Transduction of human CD34+ CD38− bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors, Mol Ther, 1, 566, 10.1006/mthe.2000.0077 · DOI
  29. Xin, 2013, Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats, Cereb Blood Flow Metab, 33, 1711, 10.1038/jcbfm.2013.152 · DOI
  30. Liu, 2015, Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment, Sci Rep, 5, 17543, 10.1038/srep17543 · DOI
  31. Smyth, 2015, Biodistribution and delivery efficiency of unmodified tumor-derived exosomes, J Control Release, 199, 145, 10.1016/j.jconrel.2014.12.013 · DOI
  32. Lavazza, 2010, Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature, Blood, 115, 2231, 10.1182/blood-2009-08-239632 · DOI
  33. Wilson, 2012, Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth, Cancer Cell, 22, 80, 10.1016/j.ccr.2012.05.014 · DOI
  34. Smith, 2010, K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate, Clin Cancer Res, 16, 338, 10.1158/1078-0432.CCR-09-2046 · DOI
  35. Uno, 2003, TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells, Blood, 101, 3658, 10.1182/blood-2002-06-1770 · DOI
  36. Burkhardt, 2013, Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells, J Clin Invest, 123, 3756, 10.1172/JCI69098 · DOI
  37. Pennati, 2015, YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation, Int J Cancer, 136, 299, 10.1002/ijc.28993 · DOI
  38. Ledford, 2015, Cancer-fighting viruses win approval, Nature, 526, 622, 10.1038/526622a · DOI
  39. Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol Ther, 21, 185, 10.1038/mt.2012.180 · DOI · Paper page
  40. Imai, 2015, Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice, J Extracell Vesicles, 4, 26238, 10.3402/jev.v4.26238 · DOI
  41. Norian, 2012, Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy, PLoS ONE, 7, e31085, 10.1371/journal.pone.0031085 · DOI
  42. James, 2014, Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells, Cancer Immunol Immunother, 63, 685, 10.1007/s00262-014-1548-5 · DOI
  43. Kalra, 2013, Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma, Proteomics, 13, 3354, 10.1002/pmic.201300282 · DOI
  44. van der Meel, 2014, Extracellular vesicles as drug delivery systems: lessons from the liposome field, J Control Release, 195, 72, 10.1016/j.jconrel.2014.07.049 · DOI
  45. Nair, 2015, Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display, Proc Natl Acad Sci U S A, 112, 5679, 10.1073/pnas.1418962112 · DOI
  46. Li, 2015, Piperlongumine and immune cytokine TRAIL synergize to promote tumor death, Sci Rep, 5, 9987, 10.1038/srep09987 · DOI
  47. Filipazzi, 2012, Recent advances on the role of tumor exosomes in immunosuppression and disease progression, Semin Cancer Biol, 22, 342, 10.1016/j.semcancer.2012.02.005 · DOI

Cited by

Sorted by citations

See all 178

Metadata

Authors
Rivoltini, L., Chiodoni, C., Squarcina, P., Tortoreto, M., Villa, A., Vergani, B., Bürdek, M., Botti, L., Arioli, I., Cova, A., Mauri, G., Vergani, E., Bianchi, B., Della Mina, P., Cantone, L., Bollati, V., Zaffaroni, N., Gianni, A. M., Colombo, M. P., & Huber, V.
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2016-07-14
Volume
22
Issue
14
Pages
3499-3512
ISSN
  • 1078-0432
  • 1557-3265
DOI
10.1158/1078-0432.ccr-15-2170
Cited by
178
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review